Skip to main content

Resverlogix Corp (RVX-T) Quote

Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 1.69
Day High 1.84
Open:1.70
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019
- GlobeNewswire - Tue Nov 12, 8:19AM CST
GlobeNewswire - CMTX
Tue Nov 12, 8:19AM CST
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has scheduled a conference call and webcast to supplement the presentation of BETonMACE results to be made during the American Heart Association's ("AHA") annual conference. As previously reported, the primary results of the BETonMACE trial will be presented on November 16 during the AHA's Scientific Sessions 2019 held in Philadelphia, Pennsylvania; additional details can be found HERE. Following the AHA presentation, the Company will host a conference call and webcast currently scheduled for 8:30 am ET on November 18, 2019.
Resverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders
- GlobeNewswire - Thu Oct 31, 6:39PM CDT
GlobeNewswire - CMTX
Thu Oct 31, 6:39PM CDT
Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. A total of 66,053,596 shares (approximately 31.54% of outstanding common shares) were represented in person or by proxy.
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
- GlobeNewswire - Fri Sep 27, 8:27AM CDT
GlobeNewswire - CMTX
Fri Sep 27, 8:27AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has issued a 10% secured convertible debenture in the principal amount of US$12 million (the "Debenture") to a wholly-owned subsidiary of ORI Star Fund LP ("ORI" or the "Fund"). The Debenture bears interest at a rate of 10% per annum and matures on September 26, 2020. The Fund may elect to convert the Debenture into common shares of the Company at a conversion price equal to the lesser of CAD$2.54 per share and the 5-day volume weighted average trading price of the common shares on the date of conversion. The Company granted the Fund a security interest in all of its assets, including its patents and other intellectual property, as security for its obligations under the Debenture. In addition, the Fund received 600,000 common share purchase warrants exercisable until December 31, 2023 at a price of CAD$2.54 per share.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.94 +92.55% increase
on 10/28/19
Period Open:1.24
Price movement based on the high, low and last over the given period.
1.94 -6.70% decrease
on 11/11/19
+0.57 (+45.97%) increase
since 10/15/19
3-Month 0.35 +417.14% increase
on 09/30/19
Period Open:2.74
Price movement based on the high, low and last over the given period.
3.04 -40.46% decrease
on 08/30/19
-0.93 (-33.94%) decrease
since 08/15/19
52-Week 0.35 +417.14% increase
on 09/30/19
Period Open:3.13
Price movement based on the high, low and last over the given period.
4.94 -63.36% decrease
on 05/08/19
-1.32 (-42.17%) decrease
since 11/15/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).